Could a common gout pill save legs and lives?

NCT ID NCT07536373

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a low-dose anti-inflammatory drug called colchicine can help people with severe leg artery disease (chronic limb-threatening ischemia) avoid amputation or death. About 200 adults who recently had a procedure to restore leg blood flow will take either colchicine or a placebo daily for 12 months. The goal is to see if colchicine improves survival without major leg amputation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIMB-THREATENING ISCHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Limb-Threatening Ischemia limb ischemia peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chi Mei Medical Center

    Tainan, 710, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shin Kong Wu Ho-Su Memorial Hospital

    Taipei, Taipei, 111, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Taipei Veterans General Hospital

    Taipei, 112, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••